Rolls-Royce stock rises in London after first buyback trades hit the tape
5 January 2026
1 min read

Rolls-Royce stock rises in London after first buyback trades hit the tape

LONDON, Jan 5, 2026, 08:30 GMT — Regular session

  • Rolls-Royce shares rose 2.1% in early London trading, hovering near a 52-week high.  1
  • The company disclosed it bought 475,882 shares in the first trades under its £200 million buyback programme.  2
  • Investors’ next focal point is the Feb. 26 full-year results, with any 2026 buyback update in the spotlight.  3

Rolls-Royce Holdings shares rose on Monday after the aero-engine maker disclosed its first share repurchases under a £200 million buyback programme. By 08:30 GMT, the stock was up 2.09% at 1,222.05 pence.  1

The timing matters because the buyback is one of the few company-specific catalysts at the start of the year, and it lands with the stock already close to a 52-week high. Investors are looking ahead to full-year results in late February for any fresh guidance and capital returns signals.  1

A share buyback is when a company buys back its own stock, typically to reduce the number of shares outstanding. Rolls-Royce said it intends to cancel the shares it repurchases, which shrinks the share count and can lift earnings per share if profits hold up.  2

In a regulatory filing on Monday, Rolls-Royce said it bought 475,882 ordinary shares on Jan. 2 at a volume-weighted average price of 1,186.4761 pence. The highest price paid was 1,197 pence and the lowest was 1,157.5 pence, the filing showed.  2

Based on the disclosed average price, the purchases amount to about £5.6 million, a small fraction of the £200 million programme. Rolls-Royce said it had 8,401,849,179 shares in issue and the same number of voting rights following the transaction.  2

The interim programme runs from Jan. 2 and is expected to complete no later than Feb. 24, with UBS executing the trades under a non-discretionary agreement, Rolls-Royce said. The company also said it will announce repurchases no later than 7:30 a.m. on the next business day.  4

The stock traded between 1,197.45 and 1,228.00 on the day, leaving it within touching distance of a 52-week high of 1,228.50. About 2 million shares had traded by early morning, compared with a three-month average of about 27 million, Investing.com data showed.  1

On valuation, Investing.com’s compilation of analyst estimates put the average 12-month price target at about 1,216 pence, roughly in line with the current share price. The proximity to that target leaves less room for error in February’s results narrative.  1

But the rally also raises the bar: any disappointment on cash generation, buyback pace or operational delivery can bite quickly in a stock sitting near its highs. Supply-chain bottlenecks have been a recurring constraint for the sector, and CEO Tufan Erginbilgic said in November that “strong performance across the group… was in line with our expectations.”  5

The next near-term catalyst is the next daily buyback disclosure, while the bigger test comes on Feb. 26 when Rolls-Royce reports 2025 full-year results and investors look for any update on buybacks for the rest of 2026.  3

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Anglo American stock jumps 3% in London as metals rally; merger clock and Feb. 5 report in focus
Previous Story

Anglo American stock jumps 3% in London as metals rally; merger clock and Feb. 5 report in focus

Lloyds stock slips as HSBC mortgage rate cuts rekindle UK price-war talk
Next Story

Lloyds stock slips as HSBC mortgage rate cuts rekindle UK price-war talk

Go toTop